K-Ras ligand-Linker Conjugate 6 is primarily used in the field of cancer research and drug development. It plays a crucial role in targeting the K-Ras protein, which is often mutated in various cancers, including pancreatic, lung, and colorectal cancers. This conjugate is designed to bind specifically to the mutated K-Ras protein, inhibiting its activity and potentially halting the growth of cancer cells. Researchers utilize this compound to study the mechanisms of K-Ras signaling pathways and to develop targeted therapies that can more effectively treat cancers driven by K-Ras mutations. Its application extends to preclinical studies, where it helps in evaluating the efficacy and specificity of new anticancer drugs.